Antibody Budoprutug to Show Early Data in Blood Disorder
Preliminary Phase 1b results will be presented in December 2026 as the drug remains investigational and not available to patients.
Updated on Nov. 4, 2026 in Biotech
Climb Bio, Inc. (Nasdaq: CLYM) will present safety, B-cell depletion, and platelet data from all three dose cohorts of its ongoing Phase 1b trial of budoprutug in previously treated adults with primary immune thrombocytopenia at the 68th American Society of Hematology Annual Meeting in New Orleans. The data is preliminary and remains at the clinical-trial stage; it is not an approved therapy.
Why it matters
Budoprutug is a novel anti-CD19 monoclonal antibody that targets B cells, and this poster is an early public look at whether depleting them can reduce platelet-attacking autoantibodies in a blood disorder. The data will show whether this approach is worth advancing beyond Phase 1b in immune thrombocytopenia, a field where B-cell-directed antibodies are being tested across several autoimmune conditions.
The evidence is preliminary, early-phase data from an ongoing Phase 1b study, so the poster will report safety and mechanism markers rather than confirmed efficacy. The source does not provide cohort sizes, platelet response rates, or depletion percentages, and those figures will only be visible once the abstract and poster are reviewed.
The players
Climb Bio, Inc.
A clinical-stage biotechnology company (Nasdaq: CLYM) headquartered in Wellesley Hills, Massachusetts, developing monoclonal antibody therapies including budoprutug.
American Society of Hematology (ASH)
The professional society that hosts the annual meeting where blood-disorder research, including immune thrombocytopenia trials, is presented and peer-reviewed abstracts are published.
The details
Budoprutug targets CD19, a protein found on B cells, and depletes those cells along with certain plasmablasts and plasma cells that produce antibodies. It is engineered with enhanced effector function, meaning it more effectively recruits the immune system to clear the cells it binds, and with low picomolar affinity, meaning it binds its target very tightly. In immune thrombocytopenia, the poster will examine whether removing these antibody-producing cells reduces the autoantibodies that destroy platelets.
Timeline
November 4, 2026: Climb Bio announced its ASH data presentation.
December 12-15, 2026: The 68th ASH Annual Meeting takes place in New Orleans, Louisiana.
December 13, 2026, 6:00-8:00 pm CT: The budoprutug poster presentation is scheduled.
The Tech Race
Budoprutug sits among B-cell-targeting antibody programs in autoimmune disease, where CD19-directed approaches are being tested across several conditions. Its FDA Orphan Drug Designation and Fast Track Designation for primary membranous nephropathy place it in a separate, later-stage program from the immune thrombocytopenia data shown at ASH.
Budoprutug is an investigational antibody that is not available to patients, and the source gives no timeline for regulatory filing, pricing, or access. The subcutaneous formulation mentioned in development is also unannounced in timing, so patients should not expect a usable treatment from this data alone.
The takeaway
Watch for the December 13, 2026 poster session, where cohort-level platelet and B-cell depletion results will show whether the early signal holds across all three doses. Readers tracking B-cell therapies should also note the separate FDA designations for membranous nephropathy as a sign of where the program may advance next.
What happens next
Climb Bio will present the budoprutug poster on December 13, 2026, from 6:00 to 8:00 pm CT at the 68th ASH Annual Meeting in New Orleans, where the full preliminary dataset will be publicly reviewable.
Further reading
For broader context on how antibody therapies are reshaping treatment for blood and immune disorders, explore our Biotech coverage.
